Takeda’s $2.5B Antitrust Charge Pushes Drugmaker to Full-Year Loss

Daily Biopharma Digest — June 5, 2026

• Takeda swung to a fiscal 2025 loss after taking a $2.5 billion legal charge tied to a pay-for-delay antitrust verdict.
• Parabilis Medicines priced its $475 million IPO to advance lead desmoid tumor candidate zolucatetide into Phase III.
• Chai Discovery entered a licensing agreement with Pfizer to accelerate AI-driven drug discovery.
• Vertex presented new pediatric ALYFTREK Phase 3 data at the European Cystic Fibrosis Conference, showing 65% of children ages 2–5 with responsive genotypes reached a key sweat chloride threshold.

What to Watch

• GLP-1 Indication Expansion — Lilly’s orforglipron trial in stress urinary incontinence represents the latest effort to extend GLP-1 therapies beyond metabolic indications, potentially opening additional multi-billion dollar markets.
• FDA Policy Flux — The pushback against Makary’s National Priority Voucher program underscores continued uncertainty around FDA policy direction and review processes under evolving leadership.
• AI Drug Discovery Validation — As partnerships like Chai-Pfizer proliferate, watch for disclosure of milestone achievements and clinical validation data that will determine whether AI platforms deliver on productivity promises.
• Antitrust Enforcement — Takeda’s $2.5B charge suggests regulators are successfully pursuing retrospective penalties, raising questions about current patent settlement negotiations across the industry.